Lupin, Inc.

Rakesh Kumar Sinha

Sudershan Kumar Arora

Neelima Sinha

Shankar Ajay

Sanjay Kumar Jain

Gourhari Jana

Ram Shankar Upadhayaya

Prathap Sreedharan Nair

Prasad Purushottam Dixit

Ram Shankar Upadhyaya

Novel pyrrole derivatives of formula (I) and their pharmaceutically acceptable acid addition salts having superior antimycobacterial activity against clinically sensitive as well as resistant strains ofas well as having lesser toxicity compared to known compounds. The use of the novel compounds of formula (I) for treatment of latent tuberculosis including Multi Drug Resistant Tuberculosis (MDR TB). The methods for preparation of the novel compounds, pharmaceutical compositions containing the novel compounds and method of treating MDR TB by administration of compounds of formula (I).

Pyrrole derivatives as antimycobacterial compounds

Novel compounds belonging to the class of oxazolidinones possessing potent antimycobacterial properties especially useful in the treatment of acid fast organisms such as-intracellular complex,and. The compound and its pharmaceutically acceptable salts act as antibacterial agents. Also mentioned is a method for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial conditions such as, drug resistant-intracellular complex,and., including administering an antimycobacterially effective amount of the compound and/or pharmaceutically acceptable salts. There is also mentioned a process for the manufacture of the compound or its pharmaceutically acceptable salts.

Antimycobacterial compounds

An antimycobacterial combination and composition for treating tuberculosis are described. The compounds used are N-(3-[[4-(3-trifluoromethylphenyl)piperazinyl]methyl]-2-methyl-5-phenyl-pyrrolyl)-4-pyridylcarboxamide of formula (I) or a pharmaceutically acceptable non-toxic salt thereof and an amount of one or more first line antitubercular drugs.

Antimycobacterial pharmaceutical composition

Growing community of inventors

Pune, India

Rakesh Kumar Sinha